PEDIATRICS Vol. 92 No. 3 September 1993, pp. 480-488
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Haemophilus Influenzae Type b Conjugate Vaccines: Recommendations for Immunization With Recently and Previously Licensed Vaccines

Committee on Infectious Diseases

This updated statement on Haemophilus influenzae type b conjugate vaccines includes recommendations for use of a newly licensed Haemophilus conjugate vaccine, and a newly licensed combination vaccine that combines one of the Haemophilus conjugate vaccines and diphtheria, tetanus toxoids, and pertussis (DTP). The statement also includes revised guidelines for the use of all conjugate vaccines. The changes concern use of different vaccine products in children younger than 15 months of age; timing for booster doses for completion of the immunization schedule in children 12 months of age and older; schedules for children in whom vaccination has been delayed in initiation, or has lapsed; choice of vaccine in children in whom vaccination against DTP or diphtheria and tetanus toxoids (DT) is deferred; number of doses for children with immunologic impairment associated with increased risk of H influenzae type b disease; and indications for rifampin prophylaxis in households where contacts have been vaccinated. Related information on the basis for these new recommendations also is given.

As of 1993, four H influenzae type b conjugate vaccines, and a combination vaccine that combines one of these vaccines with DTP, are licensed in the United States. The newly licensed conjugate vaccine consists of polyribosylribitol phosphate (PRP) conjugated to tetanus toxoid (PRP-T; ActHIB/OmniHib, prepared by Institut Merieux and distributed in the United States by Connaught Laboratories and SmithKline Beecham). The combination vaccine consists of a licensed conjugate of PRP oligomers covalently linked to diphtheria-CRM197 protein (HbOC; HIBTITER) with DTP (TRI-IMMUNOL), and is referred to as HbOC-DTP (TETRAMUNE; manufactured by Lederle-Praxis).




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. M. Fenichel
Assessment: Neurologic risk of immunization: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, May 1, 1999; 52(8): 1546 - 1546.
[Full Text] [PDF]